European Union: Recent Developments In Off-Label Use

The current interest has been stimulated, in particular, by the actions of the Italian and French authorities, who introduced cost-saving policies in 2014, to permit bevacizumab (Avastin) to be prescribed for ophthalmic indications, particularly wet age-related macular degeneration (AMD), despite the availability of ranibizumab (Lucentis) authorised for intravitreal injection for the treatment of such conditions. Avastin and Lucentis have a similar mechanism of action, but Avastin is indicated only for intravenous administration in oncology (for the treatment of colon, breast and kidney cancers).

Following the introduction of these controversial policies in Italy and France, the European Commission received a number of questions from member states and other stakeholders in relation to the issues and their associated legal and medical implications. In January 2015, EFPIA, EUCOPE and EuropaBio filed a complaint against the Italian law of May 2014 which provides for reimbursement of medicinal products used off-label even though a licensed alternative is available.1 A further complaint was issued in September 2015 in relation to the French RTU system, which allows the French medicines regulator to issue a temporary recommendation for use of a product in an unauthorised indication, for economic purposes, notwithstanding the existence of an authorised alternative treatment.2

These complaints highlight the inconsistency between the strict regulatory process for authorisation of medicinal products, based on a full and harmonised set of particulars and rigorous assessment of quality, safety and efficacy for the purposes of specific medical conditions and the promotion by national authorities of unauthorised indications for products which have not been subject to those stringent requirements for economic reasons. The position set out by EFPIA, EUCOPE and EuropaBio is also in line with the 2012 decision of the CJEU[[N:C-185/10 Commission v. Poland [2012], paragraph 38.]] which considered the supply of unlicensed medicinal products under article 5(1) of Directive 2001/83/EC, to "fulfil special needs" of particular patients. In that case, the CJEU specially stated that financial considerations cannot, in themselves, lead to recognition of the existence of special needs capable of justifying the unlicensed use of a medicinal product in preference to a product with a marketing authorisation for the indication in question.

The policies in Italy and France have resulted in litigation in the national courts. Most recently, in February 2017, the Conseil d'Etat, the French Administrative Supreme Court, rejected a challenge by Novartis against the RTU issued by the French authorities recommending use of off-label Avastin in wet AMD, despite the availability of Novartis' product, Lucentis.3 The Conseil d'Etat concluded that the provisions of the French Public Health Code were in line with EU law, as the case law of the CJEU4 shows that pursuant to article 5(1) of the Directive, an authorised medicinal product may, in certain circumstances, be used off-label, notably if its active ingredient is different from that of the product authorised for such indication, provided that the prescribing doctor deems it indispensable to use this medicine to meet the therapeutic needs of his patient.

Given this context, the Commission has finally published a much awaited report, which describes a study on off-label use of medicinal products in the EU (the Study)5 The Study provides a factual analysis of this practice across the EU, including its legal framework, its prevalence (usually cited as around 20 percent of prescriptions), a description of its drivers and a review of the existing and potential policy tools that could be used to better regulate the practice.

While the purpose of the Study was principally to describe the situation from a factual perspective, some sectors, particularly the pharmaceutical industry, have been disappointed with lack of consideration given to important issues such as off-label prescribing in the context of licensed alternatives and the promotion of off-label prescriptions for purely financial reasons. The widespread criticism of the policies of the authorities in Italy and France in relation to off-label prescribing, together with the fact that such policies have been supported by their respective courts, reflects uncertainty in this area and demonstrates an urgent need for clarification at the EU level.

The Study: Drivers of Off-Label Use

The Study lists a number of reasons why off-label use is so prevalent in the EU:

  • Regulatory incentives: Directive 2001/83/EC provides for one additional year of marketing protection if a new indication is registered in the first eight years after an authorisation is granted, provided this new indication brings significant clinical benefit over existing therapies. However, this additional year of marketing protection provides only limited benefit, particularly as doctors may prescribe a product off-label even without a company investing in such new indications. Furthermore, generic competition, low prices for off-patent medicines and increases in regulatory requirements mean there may be little incentive for a company to make such an investment.
  • Supply issues: Disruption in the manufacturing of a product or its withdrawal (for commercial or safety reasons) from the market can provoke a need for off-label use of a different product. Similarly, some products (or some indications) may be authorised in some member states but not in others, or a product may be authorised but not made available, triggering the need for off-label prescribing of available products.
  • Lack of authorised alternatives: The prescriber may have no choice but to prescribe off-label in circumstances where particular patient groups were not included in the clinical trials and are therefore not reflected in the SmPC for particular products.
  • Cost: The most controversial drivers for off-label use are related to pricing and reimbursement. In this context, the study recognises that pricing may be the reason for off-label use in those cases where the on-label product is more expensive than the off-label product and both are reimbursed. Further, there are circumstances where the off-label use of a product is reimbursed while use of the on-label product is not, leading to off-label prescribing despite the availability of the on-label product.6

The Study: Policy Options to Provide Further Guidance and Certainty Around Off-Label Use

On the basis of these findings, the Study identifies a number of policy tools that could be used to better regulate off-label use:

  • Regulating off-label prescription for specific products: Competent authorities might evaluate the risk-benefit profile of the medicine in its off-label use; only medicines with a favourable risk-benefit profile would be granted a permit to be prescribed off-label, as currently occurs in Hungary and France. In France, patients should be monitored through a protocol, and the marketing authorisation holder is required to collect safety and efficacy information, and to provide all available data to the regulatory authorities. Such systems serve to increase patient safety, and strengthen the prescriber's position with regards to liability. Their downside is that a refusal may be disadvantageous for individual patients, as off-label use may be prohibited, based on an evaluation of the average risk/benefit ratio across the population, rather than in an individual patient. The option also encounters reluctance from some companies and physicians due to the burden that these reporting obligations entail.
  • Monitoring data on efficacy and safety: Data, other than from industry-based randomised controlled trials, could be accepted as evidence for applications for authorisations; for example by accepting monitoring data on efficacy and safety, real-world data from patient registries, or pharmacovigilance data. However, in order to ensure patient safety, it should be clear which quality standards apply for these data to be acceptable.
  • EU guidance to assist with development of national guidelines of off-label prescribing: EU Guidance could be provided to establish a common ground for national treatment guidelines in member states.
  • Treatment guidelines for specific products: Off-label prescription could be regulated using protocols or professional standards prepared by the relevant professional bodies on specific off-label use, as is the case in the Netherlands. Such guidelines would provide information on the risk-benefit balance of the product, so prescribers and patients could make an informed decision.
  • Incentives for pharmaceutical companies to register new indications: The authorisation of new indications enhances patient safety and supports prescription by healthcare professionals. Industry stakeholders argued that additional incentives should be added to the EU legal framework to reward the investment needed to develop new indications, although other stakeholders considered the current incentives (including those under the Paediatric Regulation and the Orphan Drug Regulation) to be sufficient.
  • Reimbursement measures: Reimbursement systems could be amended to allow for off-label use, including: (i) reimbursing off-label use where a product is included in treatment guidelines, (ii) reimbursing off-label use for which there is no competitor on the market; and/or (iii) reimbursing off-label use where the off-label product is less expensive than its on-label competitor. The last option caused controversy among stakeholders. The authors of the Study noted the decision of the CJEU in European Commission v. Poland[[N:C-185/10 Commission v. Poland [2012].]], which confirmed that the exemption to the requirement for a medicinal product to be supplied in accordance with a marketing authorisation, under Article 5 of Directive 2001/83/EC, cannot be applied for financial reasons only. They commented that

    "it can be debated whether allowing reimbursement of off-label use in case it is less expensive than its on-label competitor is (always) against the medical need of an individual patient. Moreover, medicinal products may become available to patients who otherwise would not have access to these medicines."

    The Study states that industry was opposed to this option, but does not present any analysis of its lack of consistency with the EU medicines regulatory framework.
  • Awareness campaigns: Healthcare professionals and patients could be informed about off-label use via awareness campaigns. However, campaigns for healthcare professionals were not considered useful, as needs differ per country and per specialism. Nor were they considered useful for patients, as off-label use is not relevant for a large majority of patients.

It remains to be seen how the Commission will respond to these suggestions, and what, if any, changes will be implemented. None of the proposals involve implementing the same rigorous standard for assessment as that required by the European Directive to place a product on the market. In the meantime, the circumstances in which off-label use is permitted and even promoted by national authorities in the different member states shows substantial divergence.

Footnotes

1. Statement on bio-pharmaceutical industry complaint to the European Commission against a new Italian law promoting off-label use of medicines for economic reasons. 20 February 2015.

2. Biopharmaceutical industry files complaint against French law promoting government-initiated off-label use without the involvement or consent of patients and their physicians. 1 September 2015.

3. Conseil d'Etat, 1st–6th Chambers, 24 February 2017, No. 392459, available: https://www.legifrance.gouv.fr/affichJuriAdmin.do?oldAction=rechJuriAdmin&idTexte=CETATEXT000034081845&fastReqId=1568863364&fastPos=12

4. The Conseil d'Etat referred to C-185/10 Commission v. Poland and to C-535/11 Novartis Pharma GmbH v. Apozyt GmbH.

5. Available: https://ec.europa.eu/health/sites/health/files/files/documents/2017_02_28_final_study_report_on_off-label_use_.pdf

6. For example, in 2014, France excluded Lucentis® from drug coverage and replaced it with Avastin®.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions